Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
复制标题
DOI：
10.1016/s0140-6736(05)66374-x
复制
发表时间：
2005-04-16
期刊：
影响因子：
168.9
通讯作者：
Rössner, S
中科院分区：
文献类型：
--
作者：
Van Gaal, LF;Rissanen, AM;Rössner, S
背景 在动物模型中，大麻素 1 受体 (CB1) 阻断可产生瘦表型，对饮食引起的肥胖和相关血脂异常具有抵抗力。我们评估了利莫那班（一种选择性 CB1 阻滞剂）对超重或肥胖患者体重和心血管危险因素的影响。方法 1507 名体重指数为 30 kg/m(2) 或更大，或体重指数大于 27 kg/m(2) 且已治疗或未治疗血脂异常、高血压或两者兼有的患者被随机分配接受双盲治疗，安慰剂、5 mg 利莫那班或除轻度低热量饮食（600 kcal/天赤字）外，每日一次 20 mg 利莫那班。主要疗效终点是意向治疗人群治疗 1 年后相对于基线的体重变化。结果 使用 5 mg 利莫那班（平均 -3.4 kg [SD 5.7]；与安慰剂相比，p=0.002）和 20 mg（-6.6 kg [7.2]；p）治疗的患者 1 年体重减轻明显更大。
Background In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients.Methods 1507 patients with body-mass index 30 kg/m(2) or greater, or body-mass index greater than 27 kg/m(2) with treated or untreated dyslipidaemia, hypertension, or both, were randomised to receive double-blind treatment with placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The primary efficacy endpoint was weight change from baseline after 1 year of treatment in the intention-to-treat population.Findings Weight loss at 1 year was significantly greater in patients treated with rimonabant 5 mg (mean -3.4 kg [SD 5.7]; p=0.002 vs placebo) and 20 mg (-6.6 kg [7.2]; p